Senti Biosciences Inc

SNTI

Latest QuantConomy context for SNTI: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class

stock

Primary venue

NASDAQ

Recent signals

SEC filings

Asset profile

QuantConomy has a structured record for SNTI. More descriptive asset metadata will appear here when the platform record includes it.

Latest signal rows

Recent signals for SNTI

Scored rows are pulled from the same signal API used by the digests.

Signal	Direction	Score	Observed	Reason
fundamental operating income change	very bullish	76	May 14, 12:00 AM	SNTI (Q1 2026, operating income): grew 93.3% (-$68.78M → -$4.62M). [sequential period basis, very bullish signal]
fundamental eps change	very bullish	76	May 14, 12:00 AM	SNTI (Q1 2026, diluted eps): EPS grew 94.9% ($-2.73 → $-0.14). [sequential period basis, very bullish signal]
fundamental net income change	very bullish	76	May 14, 12:00 AM	SNTI (Q1 2026, net income): grew 93.1% (-$61.44M → -$4.22M). [sequential period basis, very bullish signal]

FUNDAMENTAL signals are experimental: the generator was recently enabled and coverage is still being validated.

Market	Exchange	Source	Asset record
SNTI	NASDAQ	alphavantage	Senti Biosciences Inc
SNTI	NASDAQ	alpaca	Senti Biosciences, Inc. Common Stock
SNTI	NASDAQ	fmp	Senti Biosciences, Inc.

Buys, last 90d

Sells, last 90d

Rows

Date	Insider	Role	Type	Shares	Price	Value	Filing
Mar 9, 2026	Rajangam Kanya	Pres. & Chief Med. & Dev. Off.	other	10,757	$0.00	$0	4 on EDGAR
Mar 9, 2026	Lu Timothy K	CEO	other	80,666	$0.00	$0	4 on EDGAR
Feb 2, 2026	Rajangam Kanya	Pres. & Chief Med. & Dev. Off.	other	1,384	$0.00	$0	4 on EDGAR
Feb 2, 2026	Lu Timothy K	CEO	other	4,191	$0.00	$0	4 on EDGAR

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.